Literature DB >> 15064862

Role of epigenetic changes in hematological malignancies.

Ulrich Lehmann1, Kai Brakensiek, Hans Kreipe.   

Abstract

Inactivation of tumor suppressor genes is an important event contributing to the development of neoplasia. In addition to the classic genetic mechanisms of deletion or inactivating point mutations, growth regulatory genes can be functionally inactivated without alterations of the primary sequence by methylation of cytosine residues in the promoter regions of the genes. After introducing epigenetic phenomena in general and the molecular basis of DNA methylation in more detail, this review will present the broad spectrum of alterations in DNA methylation patterns found in hematopoietic malignancies. In addition, the implications for therapy and prognosis will be discussed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15064862     DOI: 10.1007/s00277-003-0798-7

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  10 in total

1.  DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features.

Authors:  Laura Palomo; Roberto Malinverni; Marta Cabezón; Blanca Xicoy; Montserrat Arnan; Rosa Coll; Helena Pomares; Olga García; Francisco Fuster-Tormo; Javier Grau; Evarist Feliu; Francesc Solé; Marcus Buschbeck; Lurdes Zamora
Journal:  Epigenetics       Date:  2018-02-06       Impact factor: 4.528

Review 2.  Methylation in esophageal carcinogenesis.

Authors:  Da-Long Wu; Feng-Ying Sui; Xiao-Ming Jiang; Xiao-Hong Jiang
Journal:  World J Gastroenterol       Date:  2006-11-21       Impact factor: 5.742

Review 3.  DNA methylation as a therapeutic target in hematologic disorders: recent results in older patients with myelodysplasia and acute myeloid leukemia.

Authors:  Björn Rüter; Pierre W Wijermans; Michael Lübbert
Journal:  Int J Hematol       Date:  2004-08       Impact factor: 2.490

4.  Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin.

Authors:  M Kurimoto; H Matsuoka; N Hanaoka; S Uneda; T Murayama; T Sonoki; H Nakakuma
Journal:  Leukemia       Date:  2012-07-03       Impact factor: 11.528

5.  The SUV39H1 inhibitor chaetocin induces differentiation and shows synergistic cytotoxicity with other epigenetic drugs in acute myeloid leukemia cells.

Authors:  Y-S Lai; J-Y Chen; H-J Tsai; T-Y Chen; W-C Hung
Journal:  Blood Cancer J       Date:  2015-05-15       Impact factor: 11.037

6.  Aberrant DNA Methylation Is Associated with a Poor Outcome in Juvenile Myelomonocytic Leukemia.

Authors:  Hirotoshi Sakaguchi; Hideki Muramatsu; Yusuke Okuno; Hideki Makishima; Yinyan Xu; Yoko Furukawa-Hibi; Xinan Wang; Atsushi Narita; Kenichi Yoshida; Yuichi Shiraishi; Sayoko Doisaki; Nao Yoshida; Asahito Hama; Yoshiyuki Takahashi; Kiyofumi Yamada; Satoru Miyano; Seishi Ogawa; Jaroslaw P Maciejewski; Seiji Kojima
Journal:  PLoS One       Date:  2015-12-31       Impact factor: 3.240

Review 7.  The Emerging Role of H3K9me3 as a Potential Therapeutic Target in Acute Myeloid Leukemia.

Authors:  Laura Monaghan; Matthew E Massett; Roderick P Bunschoten; Alex Hoose; Petrisor-Alin Pirvan; Robert M J Liskamp; Heather G Jørgensen; Xu Huang
Journal:  Front Oncol       Date:  2019-08-02       Impact factor: 6.244

8.  A comprehensive microarray-based DNA methylation study of 367 hematological neoplasms.

Authors:  Jose I Martin-Subero; Ole Ammerpohl; Marina Bibikova; Eliza Wickham-Garcia; Xabier Agirre; Sara Alvarez; Monika Brüggemann; Stefanie Bug; Maria J Calasanz; Martina Deckert; Martin Dreyling; Ming Q Du; Jan Dürig; Martin J S Dyer; Jian-Bing Fan; Stefan Gesk; Martin-Leo Hansmann; Lana Harder; Sylvia Hartmann; Wolfram Klapper; Ralf Küppers; Manuel Montesinos-Rongen; Inga Nagel; Christiane Pott; Julia Richter; José Román-Gómez; Marc Seifert; Harald Stein; Javier Suela; Lorenz Trümper; Inga Vater; Felipe Prosper; Claudia Haferlach; Juan Cruz Cigudosa; Reiner Siebert
Journal:  PLoS One       Date:  2009-09-11       Impact factor: 3.240

9.  DNA methylation and mRNA expression of SYN III, a candidate gene for schizophrenia.

Authors:  Brenda C Murphy; Richard L O'Reilly; Shiva M Singh
Journal:  BMC Med Genet       Date:  2008-12-22       Impact factor: 2.103

10.  Bioinformatics analysis of the network of histone H3 lysine 9 trimethylation in acute myeloid leukaemia.

Authors:  Aishu Dong; Wenbin Yang; He Huang; Xiaohai Zhou; Zhewei He; Rongxing Yao; Wenjian Guo
Journal:  Oncol Rep       Date:  2020-05-28       Impact factor: 3.906

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.